Esophageal cancer remains one of the most lethal malignancies worldwide, with five-year survival rates stubbornly below 20% in most populations — a stark contrast to cancers that have seen dramatic treatment advances in recent decades. Understanding the distinct biology of its two major subtypes, squamous cell carcinoma and adenocarcinoma, is increasingly central to improving outcomes, and a comprehensive review in the New England Journal of Medicine synthesizes the current state of that science.
The review, spanning pages 1100–1111 of the September 2026 issue, covers the epidemiology, molecular pathogenesis, risk stratification, diagnostic approaches, and evolving treatment landscape for esophageal cancer. Squamous cell carcinoma predominates in Asia and sub-Saharan Africa, driven largely by tobacco, alcohol, and nutritional deficiencies, while adenocarcinoma has surged in Western nations in parallel with rising rates of gastroesophageal reflux disease and obesity. The piece addresses Barrett's esophagus as a key precursor lesion and examines how endoscopic surveillance and eradication strategies fit into the prevention framework. Emerging systemic therapies — including immune checkpoint inhibitors targeting the PD-1/PD-L1 axis — receive attention alongside established chemoradiotherapy regimens.
This review is notable for arriving at a moment when immunotherapy has begun to shift the ceiling on esophageal cancer prognosis, though gains remain modest compared to lung or melanoma. The dual-subtype nature of the disease complicates trial design and generalizability: findings in adenocarcinoma cohorts often do not translate to squamous populations and vice versa. For health-conscious adults, the most actionable takeaway from this body of literature remains primary prevention — managing reflux, maintaining healthy weight, limiting alcohol, and avoiding tobacco. Endoscopic screening in high-risk individuals with chronic GERD represents the clearest secondary prevention opportunity. As a comprehensive NEJM review, this represents authoritative synthesis rather than novel data, making it an essential orientation for clinicians and informed patients alike.